scholarly journals Are there any gender differences in pain perception? Clinical and experimental studies in oncology

2021 ◽  
Vol 67 (6) ◽  
pp. 755-760
Author(s):  
Elena Frantsiyants ◽  
Inga Kotieva ◽  
Elena Sheiko ◽  
Iurii Sidorenko
Keyword(s):  
Gender Differences ◽  
Chronic Pain ◽  
Cancer Patients ◽  
Pain Perception ◽  
Experimental Studies ◽  
Pain Syndrome ◽  
Living Organism ◽  
The Body ◽  
Protective Function ◽  
Mechanisms Of Development

The review considers and analyzes scientific literature on gender differences in the incidence of pain syndromes, perception of clinical pain, including that in cancer patients and in experimental oncology. The literature highlights theoretical basis, some biological mechanisms and practical results associated with gender differences. Chronic pain no longer performs a protective function and is not biologically appropriate. The review presents results of experimental studies demonstrating the important role of sex hormones and regulatory systems of a living organism in the mechanisms of development, distribution and perception of pain. Some aspects of sexual dimorphism in the processes of nociception and antinociception are covered. We present the data on the causes of chronic pain syndrome and its perception in cancer patients of both sexes indicating genetically determined sexual reactivity of the body which causes an imbalance in the function of peripheral nervous system and CNS under the influence of prolonged permanent pain in a living organism. Various pain effects have been shown to cause changes in the main types of metabolism, mobilization of adaptive metabolic mechanisms, and tissue damage. Conclusions. The high prevalence of chronic pain in both women and men with cancer, heavy humanitarian and social and economic burden explains a significant increase in fundamental and clinical research in this direction.      

scholarly journals Characterization of New TRPM8 Modulators in Pain Perception

2019 ◽  
Vol 20 (22) ◽  
pp. 5544 ◽  
Author(s):  
Carmen De Caro ◽  
Claudia Cristiano ◽  
Carmen Avagliano ◽  
Alessia Bertamino ◽  
Carmine Ostacolo ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Pain Perception ◽  
Transient Receptor Potential ◽  
Pain Modulation ◽  
The Body ◽  
Sprague Dawley ◽  
Transient Receptor Potential Melastatin ◽  
Pain Models ◽  
Excessive Activation

Background: Transient Receptor Potential Melastatin-8 (TRPM8) is a non-selective cation channel activated by cold temperature and by cooling agents. Several studies have proved that this channel is involved in pain perception. Although some studies indicate that TRPM8 inhibition is necessary to reduce acute and chronic pain, it is also reported that TRPM8 activation produces analgesia. These conflicting results could be explained by extracellular Ca2+-dependent desensitization that is induced by an excessive activation. Likely, this effect is due to phosphatidylinositol 4,5-bisphosphate (PIP2) depletion that leads to modification of TRPM8 channel activity, shifting voltage dependence towards more positive potentials. This phenomenon needs further evaluation and confirmation that would allow us to understand better the role of this channel and to develop new therapeutic strategies for controlling pain. Experimental approach: To understand the role of TRPM8 in pain perception, we tested two specific TRPM8-modulating compounds, an antagonist (IGM-18) and an agonist (IGM-5), in either acute or chronic animal pain models using male Sprague-Dawley rats or CD1 mice, after systemic or topical routes of administration. Results: IGM-18 and IGM-5 were fully characterized in vivo. The wet-dog shake test and the body temperature measurements highlighted the antagonist activity of IGM-18 on TRPM8 channels. Moreover, IGM-18 exerted an analgesic effect on formalin-induced orofacial pain and chronic constriction injury-induced neuropathic pain, demonstrating the involvement of TRPM8 channels in these two pain models. Finally, the results were consistent with TRPM8 downregulation by agonist IGM-5, due to its excessive activation. Conclusions: TRPM8 channels are strongly involved in pain modulation, and their selective antagonist is able to reduce both acute and chronic pain.

scholarly journals PROBLEM OF CHRONIC PAIN IN ONCOLOGY AND APPROACHES TO ITS RELIEF

2020 ◽  
Vol 1 (1) ◽  
pp. 32-42
Author(s):  
T. P. Protasova ◽  
A. S. Goncharova ◽  
G. V. Zhukova ◽  
E. A. Lukbanova ◽  
S. Yu. Tkachev ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Pain Syndrome ◽  
Patient Specific ◽  
Physical Factors ◽  
Nonspecific Effects ◽  
Acceptable Quality ◽  
Pathogenetic Therapy ◽  
Endocrine Status

This article reviews modern ideas about the pathogenesis of chronic pain in cancer patients and describes main approaches to its relief. Special attention is focused on factors important for the development of a patient-specific approach to the pathophysiology and management of chronic pain syndrome. These factors include genetics, gender, age, early anamnesis, patients’ immunological and endocrine status, as well as those shedding light on the pathogenetic aspects of chronic pain thus facilitating the choice of an optimal therapeutic approach. The review identifies limitations of pharmacotherapy as the major method of chronic pain management and justifies the need for alternative approaches. The latter include monitoring of the circadian rhythms of pain and various nonspecific effects, such as physical factors, psychological methods or reflex therapy. The experience and possibilities of non–pharmacological methods in the complex pathogenetic therapy of chronic pain are analysed, along with preventive measures permitting the development of chronic pain to be avoided. The pathological disorganizing and stressful role of chronic pain is considered with regard to the theory of functional systems. The pathogenetic significance of chronic pain in carcinogenesis and cancer progression is illustrated by examples from scientific literature. The authors emphasize the necessity of effective pain prevention, including invasive methods, in order to ensure an acceptable quality of life for cancer patients at any stage of the malignant process.

Abstract 326: Postural Orthostatic Tachycardia Syndrome and its Associated Chronic Pain Symptoms

2015 ◽  
Vol 117 (suppl_1) ◽  
Author(s):  
Chandralekha Ashangari ◽  
Amer Suleman
Keyword(s):  
Chronic Pain ◽  
Medical Records ◽  
Chronic Back Pain ◽  
Pain Syndrome ◽  
The Body ◽  
Postural Orthostatic Tachycardia Syndrome ◽  
Chronic Regional Pain Syndrome ◽  
High Prevalence ◽  
Pain Symptoms ◽  
Very High

Background and Purpose: The Postural Orthostatic Tachycardia Syndrome (POTS) affects primarily young women. POTS is a form of dysautonomia that is estimated to impact between 1,000,000 and 3,000,000 Americans, and millions more around the world. The symptoms of POTS are widespread because the autonomic nervous system plays an extensive role in regulating functions throughout the body. The aim of this study is to determine the chronic pain symptoms in Postural Orthostatic tachycardia syndrome (POTS) patients. Method: Two hundred fifty-five (255) POTS patients were randomly selected from our clinic (January 2014 to March 2015) , reviewed the medical records of 255 POTS patients for chronic pain symptoms and performed data analysis. Results: Two hundred thirty-three of the 255 (91%) patients are females (n=233, age 29.20 ± 10.32), Twenty-three of the 255 (9%) patients are males (n=23, age 29.70 ± 14.52).63% (161 of the 255) had Joint Pain/aches, 51% (131 of the 255) had Chronic headache, 40% (102 of the 255) had chest pain, 31% (80 of the 255) had Migraine, 30% (76 of the 255) had Chronic back pain,16% (42 of the 255) had Heartburn,8%(20 of the 255) had Chronic pleurisy, Rheumatoid arthritis, Muscle aches, Chronic regional pain syndrome and Hip aches. Conclusion: Our study is the first to characterize that Patients with postural orthostatic tachycardia syndrome (POTS) have a very high prevalence of chronic pain symptoms.

scholarly journals Indicators of the psychoemotional state of palliative polymorbid cancer patients

2021 ◽  
Vol 20 (2) ◽  
pp. 69-74
Author(s):  
U. V. Kharlamova ◽  
О. V. Kurchenkova ◽  
A. О. Abdalov ◽  
К. A. Shubina ◽  
S. I. Samodurov
Keyword(s):  
Chronic Pain ◽  
Cancer Patients ◽  
Pain Syndrome ◽  
Chronic Pain Syndrome ◽  
Psychoemotional State ◽  
Personal Anxiety ◽  
Comorbidity Index ◽  
High Level ◽  
The Impact ◽  
Palliative Patients

Introduction. Palliative care is aimed at maintaining and improving the quality of life of the patient. Without taking into account the psychosocial aspects, psychological rehabilitation is impossible in the conditions of a psychotraumatic situation of the disease.The aim of the study was to assess the psychoemotional state of polymorbid palliative cancer patients.Materials and methods. An observational, analytical, single-stage (cross-sectional) study was conducted, which included 74 cancer patients of a palliative profile. The patients underwent laboratory and instrumental examination. The following tests were evaluated: resilience (S. Maddy's method, D. A. Leontiev's adaptation), life-sense orientations, the level of subjective control, C. D. Spielberger, the severity of chronic pain syndrome; the value of the Charlson comorbidity index, the Karnovsky index (ECOG) was calculated.Results. The level of the comorbidity index was 3 [2; 5] points, the intensity of chronic pain syndrome-2 [2; 3] points, ECOG-2 [2; 3] points. In polymorbid cancer palliative patients, the presence of a belief in the impact of the struggle on the outcome of what is happening was revealed, however, patients are not always ready to act in a difficult situation. In the examined group, signs of dissatisfaction with their life in the present prevailed, the lack of sufficient freedom of choice, the existence of hope for recovery as a result of the actions of others, primarily doctors. The average (and in some cases high) level of situational and personal anxiety was noted. The association of the comorbidity index and the indicators of the life-meaning orientations test; the indicator of the general internality scale and the ECOG value; the glomerular filtration rate and the indicator of resilience, risk acceptance was revealed. A number of correlations between the indicators of the psychoemotional state and laboratory parameters (the level of hemoglobin, albumin, iron, C-reactive protein) were noted.Conclusion. In cancer patients with a palliative profile, signs of mental maladaptation were revealed. The average (and in some cases high) level of situational and personal anxiety was noted. The revealed number of correlations focuses on the role of chronic non-communicable diseases in aggravating the psychoemotional status of chronic polymorbid cancer palliative patients.

Chronic Pain

1993 ◽  
Vol 14 (5) ◽  
pp. 167-190
Keyword(s):  
Chronic Pain ◽  
Pain Perception ◽  
The Body ◽  
Psychological Disorder ◽  
Physical Factors ◽  
Recurrent Pain ◽  
Pain Syndromes ◽  
Learned Behaviors ◽  
As Stress ◽  
A Current

Chronic pain is very common, but poorly understood in Children. Both physical and subjective factors, such as stress, depression, anxiety, and learned behaviors, affect pain perception. Pain can be classified as acute, chronic, and recurrent, each varying in the proportion of these factors present. Acute pain is brief and has the largest physical component, warning the body of immediate danger. Chronic pain is longer and presents either with a current physical source or after its apparent healing. Chronic pain perception involves fewer physical factors and more subjective factors. Recurrent pain syndromes, commonly headache and abdominal and limb pains, are painful and without apparent physical cause; however, they do not always imply a psychological disorder.

Pain Syndromes Other Than Headache

2016 ◽  
Author(s):  
Edgar L. Ross
Keyword(s):  
Chronic Pain ◽  
Neuropathic Pain ◽  
Sensory Processing ◽  
Pain Syndrome ◽  
The Body ◽  
Spinal Cord Dorsal Horn ◽  
Opioid Use ◽  
Nerve Injuries ◽  
Pain Syndromes ◽  
Chronic Pain Syndromes

Pain is experienced within a complex biologic, emotional, psychological, and social context that may defy physical examination, diagnostic procedures, and laboratory tests. This chapter aims to empower internists to improve their medical practices in pain management. It provides a scientific background that covers nociception and how sensory processing occurs at multiple levels in the body. Clinical assessment is detailed, as well as diagnostic categories that include mixed or uncertain chronic pain syndromes (back pain, fibromyalgia, postamputation pain, pain from cancer and bone) and neuropathic pain syndromes (polyneuropathy, mononeuropathy multiplex, ganglionopathy, genetic disorders, focal and regional syndromes). Treatment of chronic pain can be surgical or interventional. Pharmacologic treatment for acute and chronic nociceptive pain includes special considerations for geriatric and terminal patients. For treatment of neuropathic pain, medications are the major component. One tables lists iatrogenic nerve injuries that can cause posttraumatic neuralgia and complex regional pain syndrome. Other tables detail stepwise pharmacologic management of neuropathic pain and cite recommendations on opioid use from the Centers for Disease Control and Prevention. One figure illustrates how pain transducers monitor and influence tissue conditions. Other figures show sensory processing in the spinal cord dorsal horn, physical findings in the feet of patients with bilateral foot pain from small-fiber polyneuropathy, illustrate how examination can identify specific nerve injuries causing chronic pain, and provide classification of chronic pain syndromes. This chapter contains 82 references.

Detection and treatment of akathisia in advanced cancer patients during adjuvant analgesic therapy with tricyclic antidepressants: Case reports and review of the literature

2007 ◽  
Vol 5 (4) ◽  
pp. 411-414 ◽  
Author(s):  
Hideki Onishi ◽  
Wataru Yamamoto ◽  
Makoto Wada ◽  
Tomomi Nishida ◽  
Mei Wada ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Cancer Patients ◽  
Tricyclic Antidepressants ◽  
Case Reports ◽  
The Body ◽  
Advanced Cancer Patients ◽  
Substantial Evidence ◽  
Analgesic Therapy ◽  
Appropriate Treatment ◽  
Inflammatory Drugs

ABSTRACTObjective:There is substantial evidence that tricyclic antidepressants are effective in the management of chronic pain, including cancer pain. In oncological settings, these agents are used as adjuvant analgesic drugs. However, cases of akathisia due to tricyclic antidepressants used as adjuvant analgesic therapy have not previously been reported.Case reports:Two cancer patients experiencing chronic pain who were refractory to nonsteroidal anti-inflammatory drugs and opioids were prescribed amoxapine as an adjuvant analgesic therapy for neuropathic pain. These patients developed inner restlessness and restless physical movements after amoxapine was prescribed. Although symptoms were atypical, akathisia was suspected and discontinuation of amoxapine resolved the symptoms.Results and significance of results:Akathisia should be considered in patients receiving adjuvant analgesic therapy with tricyclic antidepressants. Early detection and appropriate treatment will relieve this distressing symptom. Restless movements involving parts of the body other than the legs may be the clue to the diagnosis.

scholarly journals EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN

2019 ◽  
Vol 18 (4) ◽  
pp. 27-33
Author(s):  
R. A. Zukov ◽  
O. P. Bobrova ◽  
G. N. Gildeeva ◽  
D. V. Butuzova ◽  
E. A. Ershova
Keyword(s):  
Chronic Pain ◽  
Adverse Effects ◽  
Cancer Patients ◽  
Pain Syndrome ◽  
Chronic Pain Syndrome ◽  
Efficacy And Safety ◽  
Strong Intensity ◽  
Group I ◽  
Significant Difference ◽  
Morphine Hydrochloride

Purpose of the study: to assess the efficacy and safety of morphine hydrochloride in the form of 10 mg filmcoated tablets and 1 % solution for injection in cancer patients with chronic pain syndrome of strong intensity.Material and Methods. The study included 110 cancer patients with chronic pain syndrome of strong intensity. The study was conducted in compliance with the principles of the Helsinki Declaration, ICH GCP, GOST R 52379-2005, as well as other Russian laws regulating the conduct of clinical trials and work with opioid analgesics. Patients were randomized at a 1:1 ratio. Group I received 10 mg film-coated morphine tablets, 1 tablet orally every 4 hours for 7 days. Group II received 1 % morphine solution for injection, intramuscularly, 4 mg every 4 hours for 7 days. A Numeric Rating Scale for Pain (NRS, 0–100 mm) was used to assess the level of pain. The safety assessment was based on the collection of data on the registration of adverse events, including opioid-associated adverse effects.Results. Enteral and parenteral morphine administration for 7 days demonstrated a statistically significant decrease in the intensity of pain syndrome in cancer patients. The use of morphine hydrochloride in tablets reduced the number of additional analgesics prescribed for cancer patients. Regarding opioid-associated adverse effects, a statistically significant difference in the incidence of constipation between two groups was observed.Conclusion. The study showed that tablets and injectable dosage forms of morphine hydrochloride were comparable in efficacy and safety profile, thus predetermining the widespread clinical use of drugs produced by the domestic manufacturer in accordance with the “pain relief ladder”, proposed by WHO. 

scholarly journals The Study of Pharmacokinetics Parameters of Morphine Hydrochloride, Long-acting Tablets in Cancer Patients with Severe Chronic Pain Syndrome

2020 ◽  
Vol 9 (2) ◽  
pp. 119-123
Author(s):  
E. A. Ezhova ◽  
I. G. Kotelnikova ◽  
A. V. Teteneva ◽  
D. V. Butuzova ◽  
K. F. Tetenev
Keyword(s):  
Chronic Pain ◽  
Cancer Patients ◽  
Maximum Concentration ◽  
Study Drug ◽  
Pain Syndrome ◽  
Pharmacokinetic Parameters ◽  
Chronic Pain Syndrome ◽  
Coated Tablet ◽  
Long Acting ◽  
Morphine Hydrochloride

Introduction. Effective drug therapy for cancer patients with chronic pain syndrome (CPS) of high intensity is one of the priorities of modern healthcare. Currently, non-narcotic and narcotic analgesics are used for pain relief according to a three-steps scheme. In the absence of contraindications, it is preferable to prescribe medications per os and prolonged forms, which will allow the patient to maintain selfcare and comfort.Aim. To study the pharmacokinetic properties of a drug with a prolonged mechanism of action «Morphine hydrochloride», in a film-coated tablet formof a dosage 30 mg, in cancer patients with severe CPS.Materials and methods. For the analysis of the pharmacokinetics of the studied drug after single and multiple doses of 20 patients who received 10- day analgesic therapy with the studied drug «Morphine hydrochloride», long-acting film-coated 30 mgtablets. manufacturer FSUE Moscow Endocrine Plant, Russia. Route of administration: per os. The study duration was 17 days: screening duration up to 7 days; duration of therapy up to 10 days.Results and discussion. The concentration of morphine in plasma was determined by HPLC-tandem mass spectrometry, within 12 hours after taking the study drug (1 of long-acting, film-coated tablet 30 mg). The following pharmacokinetic parameters were obtained on Day 5: T1/2 – 6.08 ± 4.37 hours and 14.46 ± 30.86 hours, Tmax – 2.5 ± 1.86 hours, Cmax – 43.91 ± 27.24 ng/ml. Values of pharmacokinetic parameters averaged over all days are presented. It was found that T1/2 for the studied drug T1/2 is 9.21 ± 14.94 hours, Tmax 2.87 ± 2.36 hours. The average maximum concentration (Cmax) on the day of the study drug was 36.52 ng/ml.Conclusion. As a result of the study of pharmacokinetics, it was found that the drug «Morphine hydrochloride», long-acting tablets film-coated with a of 30 mg was found in serum after oral administration after 15 minutes and reaches a maximum concentration in the blood in 3 hours, the half-life is on average 9 hours, the maximum concentration is 36.52 ng/ml.

scholarly journals Мінеральний склад коренеплодів та плодів пастернаку посівного (PASTINACA SATIVA L.) сорту “Петрик”

2017 ◽  
Author(s):  
J. E. Shimorova ◽  
V. S. Kyslychenko ◽  
V. Yu. Kuznietsova
Keyword(s):  
Human Health ◽  
Experimental Studies ◽  
Living Organism ◽  
Atomic Emission ◽  
The Body ◽  
New Drugs ◽  
Quantitative Composition ◽  
Pastinaca Sativa ◽  
National Academy Of Sciences ◽  
Mineral Substances

Introduction. Human health preserving in an environment of eco-depending pathologies is the most important issue of modern medicine and pharmacy. The presence of certain mineral substances in the body in an appropriate quantity is one of the conditions for maintaining and preserving human health. Despite the fact that minerals do not have energy value, like proteins, fats and carbohydrates, many enzymatic processes in the body are impossible without their participation. Thus, the most important functions of a living organism are the realization of genetic information, the formation of subcellular structures, metabolic processes of energy production, the functioning of all organs and systems, depend on the quantitative and qualitative content of mineral substances in the body.The aim of the study – to determine macro- and microelement composition of parsnip`s roots and fruits of "Petrik" variety.Research Methods. Determination of the qualitative and quantitative composition of macro- and microelements of dried parsnip`s roots and fruits – Pastinaca sativa L. "Petrik" variety was carried out by atomic-emission spectroscopy with photographic registration in the State scientific institution "Institute for single crystals" of National Academy of Sciences of Ukraine.Results and Discussion. 19 elements were detected as a result of experimental studies. The roots predominantly contains potassium (2010.00 mg of /100 g), calcium (435.00 mg/100g), magnesium (300.00 mg/100g), sodium (270.00 mg /100 g), phosphorus (235.00 mg/100g); in fruits – potassium (1510.00 mg/kg). Roots are rich on zinc (13.40 mg/100g). Content of other elements are less than 0.1 mg /100 g.Conclusions. 19 elements were found in the roots and fruits of parsnip. Potassium (2010.00 mg/100g), calcium (435.00 mg/100g), magnesium (300.00 mg/100g) are dominated in the roots of parsnip; potassium is dominated in fruits (1510.00 mg/100 g). The results of the research will be used for further phytochemical studies of parsnip and the development of new drugs on it base. 

Sign in / Sign up

Export Citation Format

Share Document